Home / Bruce Fraser

Bruce Fraser

Stocks Alert: root9B Holdings, Inc. (Nasdaq: RTNB)

root9B Holdings, Inc. (Nasdaq: RTNB) (“RTNB”) recently declared financial results for the first quarter ended March 31, 2017 (“Q1 2017”). As formerly declared, in connection with its shift to a pure-play cybersecurity company, RTNB sold its Control Engineering, Inc. (“CEI”) partner on December 31, 2016 and the Investigative Due Diligence …

Read More »

Hanover Insurance Group, Inc. (NYSE: THG): The Hanover Enhances Education Advantage Product Suite;

As a leading provider of insurance protection for educational institutions, The Hanover Insurance Group, Inc. (NYSE: THG) recently declared it has expanded its Hanover Education Advantage product suite to include improved and broadened coverages, providing its agent partners with more opportunities to tailor insurance protection to the needs of their …

Read More »

Stocks Buzz: Trovagene, Inc. (NASDAQ: TROV)

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, declared recently that is has formally engaged PRA Health Sciences, a leading, global contract research organization (CRO), to conduct Trovagene’s Phase 1b/2 clinical trial of PCM-075, a polo-like kinase 1 (PLK1) inhibitor, in patients with acute myeloid leukemia (AML). Trovagene filed …

Read More »

Healthcare News Buzz: Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX)

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, recently declared the appointment of Charles A. Rowland Jr. to its board of directors. With more than 30 years of biopharmaceutical industry experience, Mr. Rowland provides Viking with …

Read More »

Healthcare News Updates: IsoRay, Inc. (NYSE MKT: ISR)

IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, recently declared that it has received a response from the FDA regarding the Company’s pending 510(k) application for the …

Read More »

News in Focus: Eli Lilly and Company (NYSE: LLY)

Eli Lilly and Company (NYSE: LLY) and Purdue University recently declared a planned partnershipto conduct life science research. The five-year agreement, where Lilly will provide up to $52 million, marks Purdue’s leading planned partnershipwith a single company. “Purdue has enjoyed a long history of engagement with Lilly. Now Lilly and …

Read More »

News Alert: Egalet Corporation (Nasdaq: EGLT)

Egalet Corporation (Nasdaq: EGLT) (“Egalet” or the “Company”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, recently declared the pricing of its underwritten public offering of 16,666,667 shares of its common stock and accompanying warrants to purchase up to …

Read More »